EMA after Brexit? Prioritis continues to monitor the changes
The role of the EMA within the UK will continue until 31 December 2020. But the relationship remains uncertain from...
12
Feb
22
Oct
Prioritis at ISPOR Copenhagen stand C2-037
Prioritis has launched its PrismHEOR platforms reinforcing its unique offer of daily, intelligent and reliable published and upcoming data regarding...
18
Feb
Prioritis at Pricing & Market Access Amsterdam
Prioritis will be present at the Pharma Pricing & Market Access Congress Amsterdam, March 19th - 20th 2019 Stand 28 We are proud to...
05
Nov
Prioritis at ISPOR Barcelona – Stand 201
Prioritis is looking forward to seeing you at ISPOR Europe 2018. Barcelona, 12-14 November Stand 201 We are proud to introduce a year...
09
Oct
Japanese decisions in Prismaccess and Evalumade
Prioritis is pleased to announce the incorporation of Japanese reimbursement, price and access decisions in Prismaccess and Evalumade. Japan is the...
05
Jul
Drug Reimbursement and Pricing Policy in Taiwan
Healthcare need already outstrips offer in Asia–Pacific and the gap will grow with continued increases in income, population, disease burdens,...
30
May
FDA wishes faster approval for gene therapies
FDA wishes to speed approval for new therapies aimed at diseases caused by defective genes. Gene therapies are meant to be...
14
May
Prioritis at ISPOR Baltimore
ISPOR 23rd Annual International Meeting is almost here and Prioritis is happy to announce it’s first participation in Baltimore! Our International...
13
Mar
Prioritis at Pharma Pricing and Market Access congress London
Prioritis will be present at the Pharma Pricing & Market Access Congress EU 2018. The congress will take place at the...
26
Feb
Spain, a new financing model for high economic-impact medicines
The Dirección de la Cartera Básica de Servicios del SNS y Farmacia, has announced the start-up of a new financing...
- 1
- 2